BioLineRx Receivables 2012-2025 | BLRX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

BioLineRx receivables from 2012 to 2025. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

BioLineRx receivables from 2012 to 2025. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$76.8B
Zoetis (ZTS)	$66.8B
Takeda Pharmaceutical (TAK)	$46.9B
Daiichi Sankyo, - (DSNKY)	$45.5B
BeOne Medicines - (ONC)	$31.8B
Sandoz Group AG (SDZNY)	$24.6B
Summit Therapeutics (SMMT)	$20.5B
Merck (MKKGY)	$16.7B
Shionogi (SGIOY)	$14.4B
United Therapeutics (UTHR)	$13.4B
Neurocrine Biosciences (NBIX)	$13.3B
Orion OYJ (ORINY)	$11B
IPSEN (IPSEY)	$10.5B
Corcept Therapeutics (CORT)	$7.8B
Madrigal Pharmaceuticals (MDGL)	$7.7B
Stevanato Group S.p.A (STVN)	$7.7B
Grifols, S.A (GRFS)	$6.9B
Ionis Pharmaceuticals (IONS)	$6.7B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Ono Pharmaceutical (OPHLF)	$5.2B
Soleno Therapeutics (SLNO)	$4.4B
Crinetics Pharmaceuticals (CRNX)	$3.1B
Hypermarcas (HYPMY)	$2.9B
Catalyst Pharmaceuticals (CPRX)	$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
NewAmsterdam Pharma (NAMS)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.1B
BioCryst Pharmaceuticals (BCRX)	$1.8B
Ocular Therapeutix (OCUL)	$1.8B
ARS Pharmaceuticals (SPRY)	$1.8B